A 40-year-old white man was diagnosed with precursor B-cell acute lymphoblastic leukemia (ALL) in December 2004 that was refractory to at least three reinduction attempts. BM aspiration and biopsy immediately before hematopoietic SCT (HSCT) revealed hypoplasia. He underwent an unrelated HLA-matched allogeneic HSCT with peripheral blood as stem cell source in May 2007 after receiving a conditioning regimen of cyclophosphamide 120 mg kg À1 and 1375 cGy TBI in nine fractionated doses. GVHD prophylaxis consisted of single-agent tacrolimus. BM aspiration and biopsy on day 30 after HSCT showed engraftment with no evidence of leukemia. His post-HSCT course was complicated by sepsis requiring intubation, and GVHD of the cutaneous and gastrointestinal (GI) tract treated with methylprednisolone, continued tacrolimus, mycophenolate mofetil and extracorporeal photophoresis. Following hospital discharge, he required treatment with increased immunosuppression for multiple GVHD flares (primarily glucocorticoids). Approximately 7 months after HSCT, he developed a left flank mass. An excision biopsy of the flank mass showed extra-medullary relapse (EMR) of ALL. A positron emission tomography (PET) scan performed at the time of the relapse showed multiple extramedullary sites of avid uptake involving the omentum, small bowel, pancreas, gallbladder, peri-renal fat and soft tissues of the right and left hips. A representative mass was observed in the left groin region on computed tomography (CT) scan and PET scan (Figure 1) . BM aspiration and biopsy and lumbar puncture were negative for disease. Immunosuppression was tapered and the patient subsequently developed recurrent GVHD of the skin, liver and GI with partial regression of ALL. The patient's post-transplant course was further complicated by a left hip fracture requiring closed reduction and internal fixation 8 months after HSCT. Postoperatively, persistent left thigh pain and swelling prompted magnetic resonance imaging (MRI) of the lower extremities, revealing bilateral lower extremity masses, which were confirmed to be leukemic infiltrates by fine needle aspiration. The patient died of progressive visceral leukemic infiltration in the absence of BM involvement.
PET scanning with the tracer fluorine-18 fluorodeoxyglucose (FDG), called FDG-PET, has been widely used in clinical oncology. FDG is taken up by metabolically active, glucose-utilizing cells and phosphorylated by hexokinase. The mitochondrial form is greatly elevated in rapidly growing malignant tumors. In this report, FDG-PET was used to detect EMR of leukemia involving multiple hypermetabolic lesions, which was confirmed subsequently during biopsy. Imaging techniques such as CT scanning or MRI cannot distinguish metabolically active tumor lesions. Although PET is inferior to CT and MRI for anatomic resolution, intense tumor accumulation of FDG due to a high metabolic rate allows identification of very small foci of malignancy that are not easily detected by anatomic imaging methods. Previous reports have shown the ability of PET to detect tumor foci in various neoplasms, including cancers of the thyroid, breast, lung, head and neck, colon, ovary, muscle, bone and lymph node (lymphoma).
1-3 PET imaging for acute leukemia has been described to have been useful only in two acute myeloid leukemia (AML) cases: (1) detection of extramedullary infiltrates and (2) detection of lytic bone lesions. [4] [5] [6] There are no reported cases of EMR of ALL detected by FDG-PET scan. In summary, FDG-PET scan may prove to be of value in the future in detecting and monitoring EMR of ALL following allogeneic HSCT.
